Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Inspiring CO2 circularity by introducing carbon transformation to our plates (C - 2C - Protein)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Challenges
Action type: EIC actions
Countries involved: Greece
Call: Food from precision fermentation and algae (HORIZON-EIC-2024-ACCELERATOR-02, 2024)
Start date: 2024-09-01
End date: 2026-08-31
Duration (months): 24.0
Total project cost (EUR): 3489610.8
EU funding (EUR): 2442727.56
Participants: 1
Project status: SIGNED

REVOLUTIONIZING FOOD PRODUCTION WITH CO2 INPUTS AND CARBON-NEGATIVE MICROALGAEE PROTEINS Solmeyea is a biotech company producing functional food ingredients as an alternative to both animal- & plant-based proteins. Our groundbreaking, IP-protected Hybrid Vertical Microalgae Fermentation (HVF) technology, enables microalgae fermentation using CO2 in lieu of carbon substrates and Greece's abundant Renewable Energy Sources. This combination results in the production of carbon-negative, microalgae-derived proteins in various colors requiring 0.1% of the crops-land on 200x higher yields of the same proteins. ENHANCING FOOD SECURITY, GEOPOLITICS & ECONOMIC IMPACT Our HVF not only unlocks the full potential of microalgae but also addresses EU’s critical challenges, reducing reliance on heavily commoditized and price-volatile crops and glucose. We support food security, facilitate the production of fermented CO2-derived food proteins and replace imported, highly processed and environmentally harmful crop-derived ones. We ensure the efficient production of food ingredients, contributing to national and EU GDP and empower the EU to regain independence and geopolitical competitiveness. SOLUTION: MEY PROTEIN FOR HUMAN CONSUMPTION AT SCALE MEY is the first-ever non-GMO protein produced from CO2 with the highest standards for human consumption. Through the pioneering combination of gas and microalgae fermentation, we transform SCOPE:1 CO2 into authorized, white, functional food protein. Compared to any FDA/EFSA-approved protein, our microalgae-derived MEY demonstrate 30x higher land-efficiency and 400x more sustainable in terms of water and carbon footprint. EICA SUPPORT: ADVANCING TECHNOLOGY TO TRL:9 AND BEYOND It will propel Solmeyea's CO2-Bioconversion and microalgae fermentation system to (TRL) 9, projecting an annual revenue of €190 million by 2029. Our integrated AI models ensure precision, efficiency and cost-effectiveness at both our demo and future flagship devel

Keywords: microalgae,alternative proteins,food ingredients,co2 absorbtion,bioconversion,biomass valorization
FDNA: AI-Powered Early Detection of Genetic Diseases and Rare Health Conditions (FDNA)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Germany
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2499999.0
EU funding (EUR): 2499999.0
Participants: 1
Project status: SIGNED

The European healthcare industry faces significant challenges in managing diagnosis, timely therapy, and clinical trials for genetic and rare diseases. The high costs of traditional patient recruitment methods pose substantial barriers to advancing medical research and treatment. This project proposes an innovative solution leveraging advanced artificial intelligence (AI) and phenotypic data collection to streamline diagnosis, reduce clinical trial costs, and improve patient outcomes for 450 million patients globally. Objectives: 1. Develop a comprehensive health information platform, integrating validated AI-driven image analysis with new AI-powered video and voice analysis for phenotypic data collection to expedite the diagnosis of genetic and rare diseases, improving patient outcomes. 2. Facilitate rapid recruitment of qualified participants for clinical trials. 3. Ensure compliance with EU regulations while providing high-quality, de-identified health data for research. Expected Impact: 1. Reduction of time to diagnosis of rare diseases from 5 years to 5 weeks supports patient outcomes for existing therapies and streamlines recruitment for clinical trials. The reduction of diagnosis time is made possible by leveraging visual AI in image, video, and voice analysis. 2. Improve clinical trial efficiency by enhancing recruitment and data quality, accelerating new treatments and therapies. 3. Reduce costs associated with misdiagnosis, and patient recruitment for clinical trials. 4. Enhance patient outcomes by facilitating the identification of qualified patients and providing access to specialists, new treatments, and timely therapies. 5. Advance medical research through valuable insights into disease patterns and treatment outcomes collected via our platform.

Keywords: ai driven image,video and voice analysis phenotypic data collection genetic disorders rare diseases clinical trials drug discovery patient outcomes de identified health data access to care
An innovative on-chip multi-sensing platform for single-use biopharmaceutical applications (MultiSpek)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: France
Call: EIC Accelerator Open 2024 (HORIZON-EIC-2024-ACCELERATOR-02, 2024)
Start date: 2025-01-01
End date: 2026-12-31
Duration (months): 24.0
Total project cost (EUR): 3558903.77
EU funding (EUR): 2491232.64
Participants: 1
Project status: SIGNED

The growth of biomanufacturing, characterised by an ever-increasing number of bioproduced molecules including life-saving drugs, is hampered by high bioprocessing failure rates that incur over $2 billion in annual losses for companies like Johnson & Johnson. It is also associated with significant environmental impacts, particularly in sterilisation processes. Single-use technologies have emerged as a solution, yet they require advanced sensing capabilities for full effectiveness. InSpek addresses this need with its multi-sensoron- a-chip technology, utilising waveguide-enhanced Raman spectroscopy (WERS) and Photonic Integrated Circuits (PIC). Our PICs integrate essential bioprocessing sensors — Raman spectroscopy, temperature, pH, dissolved oxygen, and others — into a single, compact platform. InSpek's non-invasive technology outperforms traditional sensors in cost and efficiency, enhancing real-time bioprocess monitoring and reducing the development time for new biotherapies.

Keywords: raman,pics,wers,optical spectroscopy,biotechnology,bioprocessing technologies,process analytical technologies
X-Verter®: Cell-level Controlled Battery System enabling software defined power (X-Verter)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Sweden
Call: EIC Accelerator Open 2024 (HORIZON-EIC-2024-ACCELERATOR-02, 2024)
Start date: 2024-12-01
End date: 2026-11-30
Duration (months): 24.0
Total project cost (EUR): 3571427.14
EU funding (EUR): 2499999.0
Participants: 1
Project status: SIGNED

To meet the goal of limiting global warming to below 2°C, energy storage capacity must increase from 140 GW in 2014 to 450 GW by 2050. Currently, only 3–4 percent of globally generated electricity is stored by utilities. Hydrogen fuel cells, while suitable for centralized and long-term storage, involve multiple conversion steps and infrastructure challenges. Battery Energy Storage Systems (BESS) are often more efficient, especially for short-duration energy storage. However, conventional BESS systems face limitations such as high conversion losses, fixed-string cell connections leading to premature battery failure, and limited scalability. BLIXT's X-Verter® addresses these challenges with software-defined power conversion based on cell-level control technology. This innovation enables BESS to generate AC sine waves directly from the battery pack, significantly reducing energy losses, bypassing weak cells, and extending battery lifespan by up to 80%. The technology is adaptable to all battery chemistries, suitable for various applications, including second-life batteries, Li-ion, supercapacitors, and more. The modular and scalable design caters to diverse capacities and customer needs, from critical infrastructure backup power to grid-scale applications. The project aims to optimize the prototype design, control software, and produce/test the BESS. Compliance and certifications for various applications will be obtained, and an initial software platform for end-users and stakeholders will be developed. Stakeholder feedback during BESS demonstrations and field trials will inform further optimization and lead to large-scale commercialization. Strong letters of support from key stakeholders validate interest in supporting the project and beyond. BLIXT's strengths lie in its motivated founders and team, a proven track record of delivering disruptive innovations, a robust IP portfolio, and recognition from industry metrics and partners.

Keywords: battery energy storage,power electronics,energy efficiency,modular multilevel converters,power conversion,cell level control,semi conductors,software defined power,battery management
Ultra-Accurate Optical Fiber Arrays for Photonics Quantum Computers and Beyond (QABLE)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Netherlands
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 21.0
Total project cost (EUR): 2499999.0
EU funding (EUR): 2499999.0
Participants: 1
Project status: SIGNED

MicroAlign develops and manufactures ultra-accurate fiber arrays tailored to the needs of photonic quantum computers, a type of quantum computer using photons as a representation of qubits. Fiber arrays are components made of multiple optical fibers bundled in a cable with a single connector. In a photonic quantum computer, they are essential for transporting photons within the computer architecture, including the photonic chip used for computation. Precise alignment between the fiber arrays and the photonic chip is crucial to prevent photon loss and signal degradation. Currently, no company provides fiber arrays with the alignment accuracy required for photonic quantum computers, making MicroAlign's technology essential for their realization. Our innovation lies in a patented micro-manipulation technology developed by our founders. This technology uses a comb of micro-actuators, each as large as a fingernail, to independently move each fiber with nanometer-scale resolution. This alignment process is rapid and scalable. Our product has been developed in close collaboration with potential customers. We have conducted technical validations and received Letters of Intent from leading quantum computer manufacturers. They all have confirmed that no competitor offers a technology remotely comparable to ours. Our innovation has reached TRL 5 (both as a product and as a manufacturing process), and will reach TRL 8 by the end of the EIC project. Besides the quantum computing industry, in the future our product will find application in many other sectors where high-performing photonic connections will soon become crucial, such as hyper-scale data centers, space, and LIDAR. Ours is an innovation with a huge market potential (a single photonic quantum computer can require up to €5 million worth of fiber arrays) and of strategic importance for the EU. The EIC fund will be invaluable to support our company with patient capital and derisk the investment of European private VCs.

Keywords: photonic chips,photonic quantum computers,optical packaging
Optimization and commercialization of the first portable and automated home dialysis system to replace traditional in-clinic care for dialysis patients. (iDA)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Israel
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

End-stage renal disease (ESRD) poses significant medical and economic challenges globally, with over 3.5 million individuals requiring continuous dialysis, mainly through dialysis clinics. However, in-clinic dialysis is time-consuming and disruptive to patients' lives. There's a growing need for portable dialysis solutions to improve efficiency and maintain patient quality of life. Despite the benefits of home dialysis, concerns such as infection risks and monitoring challenges hinder their adoption. Peritoneal dialysis (PD) is associated with high morbidity and mortality, with timely diagnosis of peritonitis being crucial for treatment success. However, delayed recognition of symptoms can negatively impact treatment outcomes. iRen-MEDICAL has developed the first portable and Digital Dialysis Clinic enabling our proprietary Intelligent Dialysis Assistant (iDA) and cloud-based Medical Supervision Portal to replace traditional in-clinic care for dialysis patients. Through active disinfection technology and remote patient monitoring features, iDA enables safe and efficient peritoneal dialysis (PD) that can be done at home, at work, or while traveling. iRen-MEDICAL’s FDA-cleared solution is set to redefine home dialysis care, making it more patient-friendly, efficient, and cost-effective. Through this project, iREN-Medical will build on the achievements of our previous Horizon 2020 awarded project, finalizing device and software optimizations, carrying out follow up usability and clinical studies to achieve relevant approval under European regulation.

Keywords: peritoneal dialysis,home dialysis,infection detection system,remote monitoring,
PalmApp: Revolutionizing Financial Accessibility and Employee Engagement through Early Wage Access, Micro-Savings, and AI-Powered Intranet with High-Fidelity Avatars for the European Workforce (PalmApp)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Czechia
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 36.0
Total project cost (EUR): 1000000.0
EU funding (EUR): 1000000.0
Participants: 1
Project status: SIGNED

PalmApp is an innovative mobile application designed to enhance financial accessibility and employee engagement in the EU. Our platform provides solutions for early wage access (EWA), micro-savings, and an AI-powered intranet with high-fidelity avatars for efficient communication. Key Features: Early Wage Access (EWA): Employees can access their earned wages before payday, providing financial flexibility and reducing stress. This feature, supported by employers, improves employee satisfaction and retention. Micro-Savings and Investment: PalmApp offers 2% cashback on purchases via the PalmApp card, which can be invested in ETFs or cryptocurrencies. This promotes immediate financial relief and encourages long-term savings and investment strategies, fostering a healthier financial lifestyle. AI Intranet with High-Fidelity Avatar: Replaces traditional intranets, ensuring all employees access critical information. Supports multiple languages, eliminating the need for translations, and features advanced voice interaction similar to Siri or Alexa. Ideal for SMEs, it includes onboarding processes, financial health assistance, legal guidance, and personalized financial literacy support. Market Potential: Target Market: Large companies in Western and Central Europe. Total Addressable Market (TAM): 280 million employees. Serviceable Available Market (SAM): 56 million employees in companies with 250+ employees. Serviceable Obtainable Market (SOM): Aiming for 30% of SAM, targeting 17 million employees. Financial and Operational Benefits: Cost Savings for the EU: By enabling early wage access and promoting financial literacy, PalmApp reduces financial distress, boosting productivity and lowering turnover. The micro-savings feature fosters financial stability, reducing reliance on state-funded social safety nets. HR Efficiency and AI Integration: The AI-powered intranet streamlines communication, enhances engagement, and provides real-time support, reducing administrative burd

Keywords: early wage access,micro savings,ai intranet,financial wellness,employee engagement,high fidelity avatar,multilingual communication,hr efficiency,eu cost savings
Microbiome Assembly and Transfer under Ecological- and Sexual Selection (MATES)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Italy,Germany
Call: MSCA Postdoctoral Fellowships 2024 (HORIZON-MSCA-2024-PF-01, 2024)
Start date: 2025-10-01
End date: 2027-09-30
Duration (months): 24.0
Total project cost (EUR): 209483.28
EU funding (EUR): 209483.28
Participants: 2
Project status: SIGNED

Bacteria, like animals, rely on transmission to spread and colonise new environments. In this context, the microbial communities that inhabit and/or transiently interact with animal hosts, collectively known as the “microbiome”, are key to animal health and fitness. The assembly of the microbiome in the hosts begins at birth and later undergoes a variety of dynamic processes influencing its establishment, function and evolution. Newly, research has theoretically recognized the importance of the microbiome associated with reproductive organs and fluids in influencing a range of reproductive processes and outcomes in males and females. The study of such communities founding the "reproductive microbiome" and the ease with which they could be tracked between hosts’ reproductive systems therefore offers key advantages for measuring the role of host-mediated transmission in microbiome assembly and variation. Still, we lack an understanding of the ecological mechanisms influencing such variation. Advances in meta ’omics are sparking interest in how microbiomes impacts physiology, propensity to disease and in turn natural and sexual selection. In addition, gnotobiotic organisms provide unique opportunities to study host-microbiota interplay with a level of experimental control that is not achievable in human studies. Coupling these two approaches should allow to pinpoint key mechanisms underlying this mutualistic relationship in a research field that is still in its infancy. In this light, we will make use of accurate observational systems that have been established to monitor interactions and mating events in the internally fertilising fish Poecilia reticulata, to measure the contribution of host contact to reproductive microbiome transmission and assembly, and how how this in turn shapes host-microbiome feedback effects on their mutual fitness. Here, we propose a research project that will fully address these challenges, providing a shift in host-microbiome research.

Keywords: sexual selection,reproductive behaviour,host microbe interactions
EOSC Focus (EOSC Focus)

Framework: Horizon Europe — Excellent Science
Programme: Research infrastructures
Theme: Research infrastructures
Destination: EOSC ecosystem
Action type: Coordination and support actions
Partnership: EOSC (co-programmed)
Countries involved: Belgium,Austria,Poland,Netherlands,Spain,Finland
Call: Supporting the development and coordination of activities of the EOSC Partnership (HORIZON-INFRA-2021-EOSC-01, 2021)
Start date: 2022-06-01
End date: 2025-05-31
Duration (months): 36.0
Total project cost (EUR): 4599653.75
EU funding (EUR): 4599653.0
Participants: 9
Project status: CLOSED

EOSC Focus will support the co-programmed EOSC Partnership in delivering its mission of establishing Open Science as the “new normal” and achieving the key objectives, which are outlined in the Memorandum of Understanding between the European Union and the EOSC Association (EOSC-A). EOSC Focus is a collaboration of eight Members of EOSC-A and the EOSC Association AISBL itself – the hub of key stakeholders in the European research environment, which provides insights on overarching themes important for the realisation of EOSC. The consortium demonstrates excellent complementarity across the diverse regions and stakeholder groups needed to ensure appropriate coverage of countries and stakeholders. EOSC Focus will provide an effective EOSC stakeholder forum; consolidate and enhance existing monitoring frameworks; identify strategic gaps to inform future iterations of the SRIA; develop and test resourcing models for a sustainable EOSC; implement the EOSC Rules of Participation; and collaborate with other EOSC-related projects, other partnerships, and international initiatives. EOSC Focus is organised into six work packages: WP 1 Project Coordination; WP 2 Stakeholder Engagement and Management; WP 3 SRIA Update and Technical Development; WP 4 Monitoring and Impact Assessment, WP 5 Sustainability of EOSC, and WP 6 Communication, Dissemination & Stakeholder Forum. The combination of these work packages will help the sometimes divergent activities of the broader stakeholder community to focus on the big goal of delivering EOSC. The impact of EOSC Focus will contribute to the increased availability, accessibility, and re-use of data. It will make research results more accessible for citizens; it will increase the quality and outreach of science and thus lead to more results from science and its innovation up-take.

Keywords: open science,eosc,collaboration,shared resources,stakeholder engagement